Rasonque (Daraxonrasib): From FDA Approval to Promising New Directions in Cancer Treatment

The treatment landscape for RAS-driven cancers is entering a new phase. RAS proteins have long been recognised as major drivers of tumour growth, but directly targeting the RAS pathway has remained one of the more difficult challenges in oncology.

A major milestone came on 26 August 2026, when the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. The approval introduces a new targeted treatment option in a disease area where options after disease progression remain limited.

The decision was supported by results from the Phase 3 RASolute 302 trial, in which patients treated with daraxonrasib experienced longer overall survival and progression-free survival than those receiving physician’s-choice chemotherapy.

Interest in daraxonrasib also extends beyond its current indication. The drug is under investigation in other RAS-driven malignancies, including non-small-cell lung cancer (NSCLC), raising the possibility that its clinical role could eventually extend beyond pancreatic cancer.

So, what exactly is Rasonque, what did the clinical evidence show, and what could daraxonrasib mean for the future of RAS-targeted cancer treatment — and for the pharmaceutical supply chain that will need to support it?

What Is Rasonque (Daraxonrasib)?

Rasonque is the brand name for daraxonrasib, an oral RAS inhibitor developed by Revolution Medicines.

RAS proteins act as molecular switches inside cells, helping regulate processes involved in cell growth, proliferation and survival. When RAS signalling becomes abnormally activated, these pathways can contribute to uncontrolled tumour growth.

Daraxonrasib takes a broader approach than therapies designed to target a single RAS mutation. It is an oral RAS(ON) multi-selective inhibitor designed to target the active, GTP-bound form of RAS. Its mechanism involves a noncovalent interaction with active RAS through a complex involving cyclophilin A, which prevents RAS from effectively engaging with downstream signalling proteins.

This matters because the approach aims to interfere directly with active RAS signalling, rather than targeting only one downstream component of the pathway.

RAS has historically been considered a difficult target in drug development. The approval of Rasonque provides clinical evidence that inhibiting active RAS can translate into meaningful outcomes for patients with advanced cancer. The FDA describes daraxonrasib as an inhibitor of the RAS GTPase family.

The FDA Approval: A New Targeted Option for Metastatic Pancreatic Cancer

On 26 August 2026, the FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy.

The approval was based on the Phase 3 RASolute 302 trial — an international, randomised, open-label, multicentre study comparing daraxonrasib with physician’s-choice standard-of-care chemotherapy in patients with metastatic pancreatic adenocarcinoma whose disease had progressed after one prior line of systemic therapy.

The recommended dose is 300 mg orally once daily, continued until disease progression or unacceptable toxicity.

This regulatory milestone is notable not only because it introduces a new targeted therapy for metastatic pancreatic cancer, but also because it offers clinical validation for directly inhibiting active RAS signalling in this setting.

It is important, however, to distinguish the approved indication from ongoing research:

• Rasonque is currently FDA-approved for metastatic pancreatic adenocarcinoma, under the specified treatment criteria.
• Its use in other tumour types remains investigational.
• Regulatory status outside the United States, including in the UK and EU, has not been established by this approval and may differ by market.

What Did the RASolute 302 Trial Show?

The pivotal RASolute 302 trial enrolled 500 patients with metastatic pancreatic adenocarcinoma who had experienced disease progression after one prior systemic treatment. Patients were randomised to receive either daraxonrasib or physician’s-choice standard-of-care chemotherapy.

The main efficacy results in the overall study population were:

Clinical Outcome	Rasonque (Daraxonrasib)	Chemotherapy
Median overall survival	13.2 months	6.7 months
Median progression-free survival	7.2 months	3.6 months
Objective response rate	30%	11%
Hazard ratio for overall survival	0.40	—

Key findings from the trial include:

• Median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy.
• The hazard ratio for overall survival was 0.40, corresponding to an estimated 60% lower risk of death during the study period for patients receiving daraxonrasib compared with the chemotherapy group.
• Progression-free survival was also longer, at 7.2 months versus 3.6 months.
• The objective response rate was 30% compared with 11% for chemotherapy.
• Both overall survival and progression-free survival showed statistically significant improvements.

The trial also included a large population with RAS G12 mutations — approximately 92% of enrolled patients — and the FDA reported improvements in overall survival, progression-free survival and objective response rate within this population as well.

These results provide important clinical evidence that targeting active RAS can produce measurable benefit in previously treated metastatic pancreatic cancer.

Why the Results Matter

The significance of RASolute 302 extends beyond a single comparison between one medicine and chemotherapy.

Pancreatic adenocarcinoma is strongly associated with alterations in the RAS pathway, making it an important setting for testing whether direct RAS inhibition can translate into improved patient outcomes.

For oncology research, the trial provides clinical support for a broader strategy: targeting RAS itself, rather than relying solely on therapies directed at downstream signalling pathways.

The approval also illustrates how advances in molecularly targeted drug development can translate into new treatment options for cancers where the therapeutic landscape has historically been limited.

How Does Rasonque Work?

Understanding Rasonque requires looking at RAS as a cellular signalling system.

RAS proteins normally switch between inactive and active states. When RAS is active, it interacts with downstream proteins that transmit signals involved in cell proliferation and survival. Cancer-associated RAS mutations can disrupt this normal regulation, resulting in persistent or inappropriate RAS signalling.

Daraxonrasib is designed to bind the active RAS(ON) state. Its mechanism involves binding to cyclophilin A and forming a complex that can interact with active RAS. This interaction interferes with the ability of RAS to engage downstream effector proteins and transmit proliferative signals.

Unlike some earlier RAS-targeted approaches that focus on a single specific mutation, daraxonrasib is described as a multi-selective inhibitor, capable of targeting multiple mutant and wild-type RAS protein isoforms in their active state.

This broader approach is one of the reasons daraxonrasib is being investigated across multiple RAS-driven cancers.

Safety and Side Effects: What Should Be Considered?

Like other anticancer medicines, Rasonque has a safety profile that needs to be considered alongside its clinical benefits.

Common adverse reactions reported with daraxonrasib include:

• Rash
• Diarrhoea
• Stomatitis
• Nausea
• Fatigue
• Vomiting
• Abdominal pain
• Oedema
• Decreased appetite
• Haemorrhage

The prescribing information also includes warnings and precautions relating to dermatologic and soft-tissue toxicity, stomatitis and other oral disorders, diarrhoea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.

In the RASolute 302 study:

• Grade 3 or higher adverse events occurred in 61.8% of patients receiving daraxonrasib, compared with 69.6% of patients receiving standard-of-care chemotherapy.
• Treatment-related discontinuations occurred in 1.2% of the daraxonrasib group, compared with 11.2% in the chemotherapy group.

Rasonque also has clinically relevant drug-interaction considerations, including interactions involving CYP3A and P-glycoprotein pathways. Treatment selection and monitoring should therefore be managed by qualified healthcare professionals using the current prescribing information.

The clinical results are encouraging, but Rasonque is not a side-effect-free therapy. Its safety profile remains an important consideration when assessing its use in clinical practice.

Rasonque and Lung Cancer: What Does the Research Show?

Pancreatic cancer is currently the only approved indication, but daraxonrasib is being studied across other RAS-driven tumours.

One of the most closely watched areas is RAS-mutant non-small-cell lung cancer (NSCLC). RAS mutations as a group are among the most common oncogenic drivers in NSCLC, occurring in approximately 30% of patients.

In September 2026, the New England Journal of Medicine published Phase 1–2 results from the RMC-6236-001 study in patients with previously treated advanced RAS-mutant NSCLC. The study evaluated once-daily daraxonrasib across a range of doses.

Among 136 patients treated with daraxonrasib at doses of up to 300 mg once daily, objective responses were observed across dose groups:

• 31% objective response rate at doses of 120 mg or less
• 34% objective response rate at doses of 160–220 mg
• 37% objective response rate at 300 mg

A particularly notable subgroup consisted of 38 patients treated at 160–220 mg once daily who were docetaxel-naive and had previously received platinum chemotherapy and anti-PD-1 or anti-PD-L1 therapy. In this group:

• The confirmed objective response rate was 42%
• The disease-control rate was 89%
• Median progression-free survival was 8.3 months
• Median overall survival was 16.0 months

These findings have supported the ongoing Phase 3 RASolve 301 study, which is evaluating daraxonrasib against docetaxel in previously treated RAS-mutant NSCLC.

The NSCLC findings are notable because they suggest the multi-selective RAS(ON) approach may have activity in another major RAS-driven cancer. However, the results come from an early-phase study and require confirmation in a larger randomised trial.

An Important Regulatory Distinction

The lung-cancer findings are promising, but they should not be confused with an approved indication.

Rasonque is not currently FDA-approved for lung cancer. The NSCLC programme remains investigational, and the Phase 1–2 findings will need to be evaluated further in larger randomised studies before any potential regulatory expansion.

This distinction is particularly important for pharmaceutical and healthcare professionals, as clinical trial evidence does not automatically translate into an approved indication. Regulatory status can differ between countries and may change as additional evidence becomes available. For UK-based stakeholders, current MHRA guidance on human medicines can be reviewed directly via GOV.UK and the MHRA.

What Could Rasonque Mean for the Oncology Pharmaceutical Market?

The significance of Rasonque extends beyond a single newly approved medicine.

For the pharmaceutical industry, its development reflects a broader movement towards molecularly targeted oncology, where treatment strategies are increasingly shaped by the biological characteristics of a tumour rather than by cancer location alone.

RAS is particularly important in this context because alterations in the pathway occur across multiple tumour types. If ongoing studies demonstrate meaningful clinical benefit in additional cancers, the potential role and demand for daraxonrasib could expand considerably.

For pharmaceutical supply-chain teams, new targeted therapies also create practical considerations around:

• Product availability
• Regulatory status by market
• Market access
• Sourcing and procurement channels

A medicine may attract substantial clinical interest before it has received regulatory approval in a particular country or for a particular indication. This makes accurate interpretation of licensing status essential when evaluating procurement opportunities. Logan Pharmaceuticals’ compliance framework is built around this principle — supporting partners with sourcing decisions that reflect current, verified regulatory status.

The distinction between approved and investigational use is especially relevant for Rasonque. While the medicine now has an FDA-approved role in metastatic pancreatic adenocarcinoma, its use in areas such as NSCLC remains under clinical investigation.

What Should the Industry Watch Next?

Several developments will help determine how far the role of daraxonrasib ultimately expands:

1. Phase 3 NSCLC data — The RASolve 301 trial will help determine whether the activity observed in earlier research translates into improved outcomes when daraxonrasib is compared with an established treatment such as docetaxel.
2. Additional RAS-driven cancers — Researchers are continuing to investigate daraxonrasib across other solid tumours where RAS signalling plays an important role. Results from these programmes will help establish whether the drug’s multi-selective mechanism can be applied more broadly.
3. Earlier treatment settings — Future studies may clarify whether RAS-targeted therapy could have a role earlier in the treatment pathway, rather than primarily after previous systemic therapy.
4. Combination strategies — Researchers are also exploring how RAS inhibition could potentially be combined with other anticancer approaches. Combination treatment may become increasingly important if resistance mechanisms limit the effectiveness of RAS inhibition alone.
5. Regulatory expansion — Any future indication would depend on clinical evidence and regulatory review in the relevant market. Approval in one country or for one tumour type does not automatically establish an indication elsewhere.

For wholesalers and pharmaceutical procurement teams, these developments are worth monitoring closely. Regulatory approvals, clinical trial outcomes and changes in treatment guidelines can all influence demand, sourcing requirements and market availability. Our blog tracks these developments as they emerge.

What Does the Future Hold for RAS-Targeted Therapy?

The approval of Rasonque represents a significant step in a much larger scientific effort to make RAS a clinically actionable cancer target.

For years, RAS was considered one of the more difficult targets in oncology. The development of medicines capable of interacting with active RAS has changed the direction of research and created new opportunities for targeting cancers driven by abnormal RAS signalling.

Daraxonrasib is part of this wider evolution. Its Phase 3 pancreatic cancer results provide evidence that broad RAS inhibition can produce clinically meaningful outcomes, while the emerging NSCLC data suggest that the approach may have applications beyond a single tumour type.

The next stage will be determining how broadly these findings can be translated into routine clinical practice.

For now, Rasonque’s established role is clear: it provides a new targeted treatment option for eligible adults with metastatic pancreatic adenocarcinoma following prior systemic therapy, or for patients who are not candidates for multiagent systemic therapy. Its potential in other cancers remains a subject of ongoing research.

Conclusion

Rasonque (daraxonrasib) has quickly become an important development in the field of targeted oncology.

Its FDA approval on 26 August 2026, supported by the RASolute 302 Phase 3 trial, provides eligible patients with metastatic pancreatic adenocarcinoma a new oral treatment option and demonstrates the potential clinical value of targeting active RAS signalling.

At the same time, emerging research in RAS-mutant NSCLC is expanding interest in where daraxonrasib could eventually fit across oncology. The NSCLC use remains investigational, but the latest clinical data reinforce the wider importance of developing therapies that directly address RAS-driven disease.

As research progresses, Rasonque will be worth watching not only from a clinical perspective, but also from the standpoint of pharmaceutical supply, market access and the evolving demand for targeted oncology medicines.

This article is provided for general informational purposes for pharmaceutical, healthcare and supply-chain professionals. It does not constitute an advertisement or promotion of Rasonque (daraxonrasib), and does not represent an offer to supply this or any specific product. Any enquiry regarding a specific medicine will be handled in accordance with applicable regulatory requirements, including its licensing status in the relevant market.

Sources

• U.S. Food and Drug Administration (FDA). FDA Approves First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer, 26 August 2026.
• U.S. Food and Drug Administration (FDA). FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma.
• O’Reilly EM, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2026;395:325–337. DOI: 10.1056/NEJMoa2605555.
• Arbour KC, et al. Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395:882–893. DOI: 10.1056/NEJMoa2504059.
• RASONQUE (daraxonrasib) U.S. Prescribing Information. Revolution Medicines.
• ClinicalTrials.gov. RASolute 302 and RASolve 301 clinical trial information.
• MHRA — How MHRA Authorises Medicines, GOV.UK.

This article is intended as general information for pharmaceutical, healthcare and supply-chain professionals. It is not medical advice. Treatment decisions should be made by qualified healthcare professionals, and regulatory status may differ between countries and change as new evidence becomes available.